Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Thomas Powles; Mark Kockx; Alejo Rodriguez-Vida; Ignacio Duran; Simon J. Crabb; Michiel S. van der Heijden; Bernadett Szabados; Albert Font Pous; Gwenaelle Gravis; Urbano Anido Herranz; Andrew Protheroe; Alain Ravaud; Denis Maillet; Maria Jose Mendez; Cristina Suarez; Mark Linch; Aaron Prendergast; Pieter-Jan van Dam; Diana Stanoeva; Sofie Daelemans; Sanjeev Mariathasan; Joy S. Tea; Kelly Mousa; Romain Banchereau; Daniel Castellano

doi:https://doi.org/10.1038/s41591-023-02312-9

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Thomas Powles, Mark Kockx, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. van der Heijden, Bernadett Szabados, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Pieter-Jan van Dam, Diana Stanoeva, Sofie DaelemansSanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Romain Banchereau, Daniel Castellano

Research output: Contribution to journal › Comment/Letter to the editor › Academic

Abstract

Correction to: Nature Medicine. Published online 4 November 2019. In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.

Original language	English
Pages (from-to)	3271
Number of pages	1
Journal	Nature medicine
Volume	29
Issue number	12
Early online date	2023
DOIs	https://doi.org/10.1038/s41591-023-02312-9
Publication status	Published - Dec 2023

Access to Document

https://doi.org/10.1038/s41591-023-02312-9

Cite this

Powles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., van der Heijden, M. S., Szabados, B., Pous, A. F., Gravis, G., Herranz, U. A., Protheroe, A., Ravaud, A., Maillet, D., Mendez, M. J., Suarez, C., Linch, M., Prendergast, A., van Dam, P.-J., Stanoeva, D., ... Castellano, D. (2023). Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7). Nature medicine, 29(12), 3271. https://doi.org/10.1038/s41591-023-02312-9

@article{6afe2640f04b40db9f7f467a297accf4,

title = "Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)",

abstract = "Correction to: Nature Medicine. Published online 4 November 2019. In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.",

author = "Thomas Powles and Mark Kockx and Alejo Rodriguez-Vida and Ignacio Duran and Crabb, {Simon J.} and {van der Heijden}, {Michiel S.} and Bernadett Szabados and Pous, {Albert Font} and Gwenaelle Gravis and Herranz, {Urbano Anido} and Andrew Protheroe and Alain Ravaud and Denis Maillet and Mendez, {Maria Jose} and Cristina Suarez and Mark Linch and Aaron Prendergast and {van Dam}, Pieter-Jan and Diana Stanoeva and Sofie Daelemans and Sanjeev Mariathasan and Tea, {Joy S.} and Kelly Mousa and Romain Banchereau and Daniel Castellano",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer Nature America, Inc.",

year = "2023",

month = dec,

doi = "https://doi.org/10.1038/s41591-023-02312-9",

language = "English",

volume = "29",

pages = "3271",

journal = "Nature medicine",

issn = "1078-8956",

publisher = "Nature Publishing Group",

number = "12",

}

Powles, T, Kockx, M, Rodriguez-Vida, A, Duran, I, Crabb, SJ, van der Heijden, MS, Szabados, B, Pous, AF, Gravis, G, Herranz, UA, Protheroe, A, Ravaud, A, Maillet, D, Mendez, MJ, Suarez, C, Linch, M, Prendergast, A, van Dam, P-J, Stanoeva, D, Daelemans, S, Mariathasan, S, Tea, JS, Mousa, K, Banchereau, R & Castellano, D 2023, 'Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)', Nature medicine, vol. 29, no. 12, pp. 3271. https://doi.org/10.1038/s41591-023-02312-9

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7). / Powles, Thomas; Kockx, Mark; Rodriguez-Vida, Alejo et al.
In: Nature medicine, Vol. 29, No. 12, 12.2023, p. 3271.

Research output: Contribution to journal › Comment/Letter to the editor › Academic

TY - JOUR

T1 - Publisher Correction

T2 - Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

AU - Powles, Thomas

AU - Kockx, Mark

AU - Rodriguez-Vida, Alejo

AU - Duran, Ignacio

AU - Crabb, Simon J.

AU - van der Heijden, Michiel S.

AU - Szabados, Bernadett

AU - Pous, Albert Font

AU - Gravis, Gwenaelle

AU - Herranz, Urbano Anido

AU - Protheroe, Andrew

AU - Ravaud, Alain

AU - Maillet, Denis

AU - Mendez, Maria Jose

AU - Suarez, Cristina

AU - Linch, Mark

AU - Prendergast, Aaron

AU - van Dam, Pieter-Jan

AU - Stanoeva, Diana

AU - Daelemans, Sofie

AU - Mariathasan, Sanjeev

AU - Tea, Joy S.

AU - Mousa, Kelly

AU - Banchereau, Romain

AU - Castellano, Daniel

PY - 2023/12

Y1 - 2023/12

N2 - Correction to: Nature Medicine. Published online 4 November 2019. In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.

AB - Correction to: Nature Medicine. Published online 4 November 2019. In the version of this article initially published, under the Methods subsection “Trial design and patient population,” the dosing of atezolizumab was wrongly stated as “1,200 mg, three times weekly.” The correct dose is 1,200 mg, once every three weeks.

UR - http://www.scopus.com/inward/record.url?scp=85150419311&partnerID=8YFLogxK

U2 - https://doi.org/10.1038/s41591-023-02312-9

DO - https://doi.org/10.1038/s41591-023-02312-9

M3 - Comment/Letter to the editor

C2 - 36944799

SN - 1078-8956

VL - 29

SP - 3271

JO - Nature medicine

JF - Nature medicine

IS - 12

ER -

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, van der Heijden MS et al. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7). Nature medicine. 2023 Dec;29(12):3271. Epub 2023. doi: https://doi.org/10.1038/s41591-023-02312-9

Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

Abstract

Access to Document

Other files and links

Cite this